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Abstract
Hepatitis B infection is a major public health issue with a high mortality rate. It is caused by hepatitis B virus (HBV), a
small incomplete hepadnavirus with several open reading frames (ORF). High mutation rates of the HBV ORFs due to
the virus’ replicating strategy are associated with the development and emergence of mutant strains, which may result in
occult infections that are undetectable by conventional diagnostic assays. In this study, we first investigated the presence and prevalence of hepatitis B surface antigen (HBsAg) and HBV DNA among 204 patients visiting the specialist
hospital in Osogbo, Nigeria, by using the Acumen diagnostic test strip kit and PCR amplification of the surface antigen
gene. Then, we compared the positive results detected by both assays. The mean age of the participants was 30.5 years.
Twenty-two (10.78%) cases were positive in the HBsAg test, and 69 (33.82%) cases were positive for HBV DNA. Fifty-four false-negatives (26.47%) and four false-positives (1.96%) were detected by HBsAg. The rapid diagnostic test kit
is less sensitivity and has lower detection capability compared with the PCR-based assay, which indicates the presence
of mutant HBV strain(s). The results of this work demonstrate that HBsAg is endemic in Nigeria and that HBV DNA is
highly prevalent among the population. Our findings highlight the need for immediate action to prevent the further
spread of infection.
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transplant, and transmission from carrier mothers to
their babies during the perinatal period. The symptoms
of HBV infection include jaundice, dark urine, fatigue,
nausea, vomiting, and abdominal pain. The disease is an
important occupational hazard for health workers [5, 6].

Introduction
Hepatitis B virus (HBV) is a small enveloped hepatotropic virus that possesses a partially double-stranded
relaxed circular DNA genome [1]. It belongs to the
Hepadnaviridae family and can cause both acute and
chronic infections [2]. As many as 250 million people
worldwide are chronically infected with the virus, and
0.62 million deaths resulting from the long-term complications of the disease are estimated to occur annually.
Thus, HBV remains a major global public health challenge despite the wide availability of effective vaccines
against the virus [2–4]. The prevalence rate of HBV in
different parts of the world varies to some extent; for
example, prevalence rates of 6.2% and 6.1% have been
reported for the Western Pacific and African regions,
respectively. Prevalence rates of 3.3% for the Eastern
Mediterranean, 2% for Southeast Asia, 1.6% for the
European region, and 0.7% for the Americas have also
been recorded [5].

Implementing preventive measures against the spread of
HBV infection is vital for global health safety. Hence,
the World Health Organization (WHO) [5] recommends
that all blood donations be tested for HBV to ensure
blood safety and avoid accidental transmission to persons receiving blood products as a preventive measure
against viral infection. The hallmark of this testing is the
detection of hepatitis B surface antigen (HBsAg), a serological marker that is present in the acute and chronic
phases of the disease [7]. This antigen appears in the
serum within 1–10 weeks after exposure to the virus,
and its persistence for over 6 months indicates chronic
HBV infection [8]. However, mere detection of HBsAg
presence is inadequate to establish HBV infectivity [9].

HBV can be transmitted by sexual contact with an infected individual, parenteral exposure to infected body
fluids, especially blood, during blood transfusion, organ

Chronic hepatitis B is the most frequent cause of chronic liver diseases, including cirrhosis, and hepatocellular
carcinoma (HCC) worldwide [6, 10]. Current approach134
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es to manage this infection, therefore, focus on improving long-term survival by slowing progression to cirrhosis and HCC [5]. However, the definition of a chronic
HBV carrier has been complicated by the finding that
some individuals have HBV DNA in their circulation
despite the absence of detectable HBsAg in their serum
or plasma [11, 12]. This discordant serological and viral
nucleic acid profile is called occult hepatitis B infection
(OBI) and has been defined as the long-lasting persistence of HBV DNA in the liver of patients with a
HBsAg-negative status with or without antibodies to
HBsAg and/or antibodies to hepatitis B core antigen,
which are serological markers of previous exposure.
These HBV blood markers are used to diagnose and
identify the infection stage (previous or present infection) of patients [13, 14].
Mutations in certain regions of the HBV genome are
commonly associated with OBI [22, 15–17]. Mutant
strains of HBV have been detected in acute and chronic
infections and, in the HBV open reading frames (ORFs),
including preS/S, polymerase, precore/core, and X. The
preS/S ORF codes for molecules that form HBsAg,
which is the antigen recognized for host immunity and
aids in the attachment of the virus to hepatocytes. The
polymerase ORF codes for the reverse transcriptase
domain of the HBV polymerase, and the precore/core
ORF codes for the core nucleocapsid and envelope antigen [18]. Different methods for detecting different
strains of the HBV polymerase gene include conventional DNA sequencing, PCR-based assays and reverse
hybridization [19, 20].
The mechanism of OBI is incompletely understood;
however, both viral and host-related factors resulting in
sequence variations in HBV genomes and suppression
of viral replication, respectively, have been implicated as
possible causes of undetectable HBsAg in the presence of
circulating HBV DNA [11, 14, 21]. Some studies have
shown that the sG145R mutation as well as several other
mutations within the “a” determinant of HBsAg decrease
the binding affinity of the surface antigen to monoclonal
antibodies developed against it, leading to a false-negative
HBsAg status [12, 22, 23]. Similarly, mutations in the S
region have been implicated in the reduced expression
of hepatitis B surface proteins [12, 24]. Other mutations,
such as the substitution of guanine with adenine at position 458 of the surface gene, which interferes with the
splicing of the S gene mRNA, as demonstrated by Hass
et al. [25], as well as therapy-induced amino acid substitution in the HBV polymerase and surface gene, have
been associated with OBI [26]. HBsAg mutations could
create false-negative HBV results during routine screening and lead to occult HBV infection, thereby posing a
significant diagnostic challenge [27].
The prevalence rates of OBI range from 1% to 95%
worldwide and are influenced by several factors, such as
Makara J. Sci.

the endemicity of HBV, various cohort characteristics,
including the presence of chronic HCV or other comorbid diseases, and the performance characteristics of laboratory techniques [28]. OBI is generally more common in locations where HBV is endemic, such as Asia
and Africa, than in other regions; its prevalence is also
higher in patients with hepatitis C virus (HCV) [12].
The clinical significance of OBI is reinforced by the
potential risk of HBV transmission through blood transfusion, hemodialysis, and solid organ transplantation;
cryptogenic liver disease; liver cirrhosis and HCC; and
interference with antiviral treatment for patients with
chronic HCV disease [13]. Despite the significant role
of OBI in global health safety, however, knowledge of
OBI remains limited. Moreover, a testing regimen with
suitably high sensitivity and specificity for detecting
OBI has yet to be incorporated into the HBV testing
algorithms of many resource-limited countries, including Nigeria [29].
Very few studies have reported on the presence and
circulation of mutant HBV strains in Nigeria [30]. Thus,
the present study aims to detect and determine the prevalence of HBsAg and HBV DNA among female patients
visiting the State Specialist Hospital in Osogbo, Osun
State, Nigeria.

Materials and Methods
Ethics statement. Ethical clearance (No. HREC/27/04/
2015/SSHO/029) for this study was obtained from the
institutional review board of the State Specialist Hospital,
Osogbo, Nigeria. Written informed consent was
obtained from each patient in the presence of at least
one witness prior to their participation in this research.
Sample size and sampling period. A total of 204
female patients with ages ranging from 1 year to 50
years and visiting the State Specialist Hospital, Osogbo,
Nigeria, during the period of February 2017–April 2018
were recruited to this study. Access to the subjects’
medical histories and other demographic characteristics
during the sampling period was not available.
Serological Detection of HBsAg. Approximately 2 mL
of whole-blood samples was collected into EDTA
bottles from each patient, and serum was obtained from
each blood sample. Each serum sample was tested for
HBsAg by using a commercial HBsAg rapid test kit
(Acumen Diagnostic Test Strip; Acumen Labs and
Diagnostic Center, Bangalore, India).
Molecular assay for HBV DNA. Extraction of
hepatitis B virus DNA. HBV DNA was extracted from
whole-blood samples using ZR viral DNA extraction
kits (Zymo Research, USA) according to the
manufacturer’s instructions.
September 2020  Vol. 24  No. 3
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Viral gene amplification. Nested PCR was conducted
to amplify a 143 bp region of the surface gene (base
pairs 303–446) by using the extracted genomic DNA as
template DNA. The forward primer (HBV-FP)
5’ACTCACCAACCTCTTGTCCT3’ and the reverse primer
(HBV-RP) 5’GACAAACGGGCAACATACCT3’, which
amplifies both wild- and mutant-type HBV, were used
for primary and secondary PCR under the same thermal
cycling conditions. Each reaction mixture comprised a
total volume of 25 µL, including 12.5 µL of the PCR
master mix (2× quick tar master mix Bio research), 1 µL
each of the forward and reverse primers (10 µm), 5.5 µL
of nuclease-free water, and 5 µL of the extracted DNA
sample. Primary amplification was carried out using the
extracted DNA template. Secondary PCR was done
using the PCR products of the primary amplification.
The thermal cycling conditions for the amplifications
are as follows: 95 °C for 10 min, 35 cycles of 94 °C for
40 s, 56 °C for 60 s, elongation at 73 °C for 2.5 min
followed by 72 °C for 4 min. Negative controls were
integrated in all PCR rounds.
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for example, more cases were positive for HBsAg and
HBV DNA in the age groups 21–30 years and 31–40
years than in the other age groups. Individuals within
the age group 21–30 years, followed by those in the age
group 31–40 years, showed the highest incidence of
seropositive results for both HBsAg and HBV DNA
(Figure 2).

Figure 1. Comparison of Positive Results Detected by
Molecular Assay and Rapid Testing
Molecular assay (PCR) revealed a greater number of positive
results than the rapid kit assay.

Gel electrophoresis. The PCR products were assessed
by electrophoresis with 2% agarose gel with a 50 bp
DNA ladder at 90 V. Electrophoresis was conducted for
45 min, and the band patterns were observed under
ultraviolent light.
Statistical analysis. Descriptive statistics of the
participants’ ages were obtained using Microsoft Excel
2010, and the frequencies of HBsAg- and HBV DNApositive results between the serological (HBsAg) and
molecular (nucleic acid) methods was compared among
participants. Finally, the HB detection accuracy of the
two methods was assessed by calculating the frequency
of HB false-positive and -negative results.

Results
A total of 204 participants were included in this study.
All of the participants were female, and their mean age
was 30.5 years. HBsAg and HBV DNA detection was
carried out in all 204 cases. Twenty-two (10.78%) cases
were positive and 182 (89.22%) cases were negative for
HBsAg; by comparison, 69 (33.82%) cases were positive for HBV DNA (Figure 1). The frequencies of HBsAgand HBV DNA-positive results among age groups are
shown in Figure 2. Figure 3 compares the total number
of samples and proportions of seropositivity and negativity for both assays. No individual in the age
group 11–12 years revealed a positive HBsAg or HBV
DNA result. Fifty-four (26.47%) cases yielded falsenegative results, while four (1.96%) cases yielded falsepositive results (Table 1). The agarose gel electrophoresis results of some samples are shown in Figure 4.
The distribution of cases according to age and HBsAgand HBV DNA-positivity was not evenly distributed;
Makara J. Sci.

Figure 2. Comparison of Numbers of Persons (in Age
Groups) Positive for HBsAg and HBV DNA
The age groups 21–30 years and 31–40 years showed the highest
incidence of seropositivity for both HBsAg and HBV DNA.

Figure 3. Distribution of HBsAg and HBV DNA Seropositivity and Seronegativity According to Age
Group
Positive HBV DNA and HBsAg was recorded among the age
groups 21–30 years and 31–40 years but not among the age
group 11–20 years. HBV DNA but not HBsAg was detected
among the age groups 1–10 years and 41–50 years.
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Table 1. Frequencies of False-negative and -positive
Results Obtained by Comparison of the Rapid
Test and Molecular Assay Results

Figure 4. Agarose Gel Electrophoresis Results of the PCR
Assay of Some Samples
Samples in lanes 1–7 are HBV DNA positive. The expected
DNA size is 143 bp.

Discussion
The detection and prevalence of HBsAg and HBV DNA
in a portion of the female population of Osogbo, Osun
State, Nigeria, is reported in this work. The results
confirm the inclusion of Nigeria in the HBV crescent, as
reported by Faleye [30]. HBV infection is widely spread
and constitutes a major public health problem in subSaharan Africa. According to the WHO, a high
endemicity of HBV infection is defined as a HBsAg
prevalence greater than 7% [31]. In this report, 10.6%
HBsAg prevalence was detected using the rapid kit and
34.6% HBV DNA prevalence was revealed by the PCR
molecular-based assay. These results confirm the
endemicity of HBV infection in the study population.
Obi [32], Olokoba [33], and Eke [34] reported the high
prevalence of HBV among pregnant women in different
parts of the country. The high prevalence of HBsAg in
the study population may be due to poor awareness,
weak vaccination programs, and other risk factors that
could promote the spread of HBV infection. In this
study, the groups with the highest numbers of HBsAgpositive patients were those including sexually active
and fertile persons. Thus, sexual activity and fertility
may be contributing factors to the high prevalence of
HBV infection recorded. A consequence of HBV
infection in females of this age group (21–30 years and
31–40 years) is the high risk of vertical transmission
(i.e., mother to child); the HBV-contaminated newborn
may develop as an asymptomatic chronic carrier and
progress to liver cirrhosis and HCC. Our results also
showed significant differences in the numbers of
positive HBsAg and HBV DNA cases detected in each
age group.
Infected hepatocytes often contain covalently closed
circular DNA with prolonged existence in their nucleus,
which leads to difficulty in clearing chronic HBV
infection [35]. Antiviral therapies to treat HBV infection
Makara J. Sci.

Number of persons positive for HBV DNA
(molecular assay)

69 (33.82%)

Number of persons positive for HBsAg (rapid
test kit)

22 (10.78%)

False-negative results (negative for HBsAg but
positive for HBV DNA)

54 (26.47%)

False-positive results (positive for HBsAg but
negative for HBV DNA)

4 (1.96%)

include nucleoside/nucleotide analogs (NA), which aim
to clear and prevent the progression of liver disease to
cirrhosis and HCC. NAs are designed to target one or a
combination of synthesis of the short negative DNA
strand, DNA-dependent DNA replication or reverse
transcription from pregenomic RNA to negative DNA
strand [35]. However, some factors, such as HBV
genetic variability, enable HBV to persist and resist
NAs, which often leads to increases in HBV infection
prevalence and the emergence of mutant strains. These
factors/conditions may play various roles in promoting
the high prevalence rate of HBsAg in the studied
population. Non-detection of HBV via normal routine
screening leading to occult infections is often caused by
mutations in HBsAg [27]; hence, molecular-based
assays should be used for HBV detection. In this study,
comparison of the molecular assay and rapid test
methods revealed false-negative and -positive results.
Viral DNA was successfully isolated and amplified
from 37 (21.5%) samples that were HBsAg-negative.
Our findings demonstrated a high number of falsenegative results obtained via the rapid diagnostic kit.
This result is indicative of the presence of a large
number of HBV mutant strains within the population
studied. Mutations in HBsAg have been implicated to
cause decreases in the binding affinity of the surface
antigen to monoclonal antibodies and the expression of
HB surface protein, which produces false-negative
HBsAg results [12, 21]. This report is in agreement with
Foy [27], who reported on a hemodialysis patient with
high levels of HBV DNA and antibody but was HBsAg
negative. Our findings also agree with those of Faleye
[30] and Erhabor [37], who reported false-negative
results among blood donor samples in Northwestern
Nigeria.
HBV rapid-screening test kits are inferior compared
with enzyme- and molecular-based assays and often
associated with false-negative and -positive results. The
September 2020  Vol. 24  No. 3
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diagnostic accuracy, sensitivity, and specificity of HBV
rapid-screening test kits are unreliable, and other assay
techniques are usually necessary to confirm a diagnosis
[30, 36, 37]. HBV rapid diagnostic test kits are known
to vary in terms of their ability to detect certain
genotypes and variants of HBsAg [27]. The inability of
rapid test kits to detect HBsAg in some blood samples
despite the detection of viral DNA by the molecular
PCR technique may indicate HBV genetic variability
among the population or an infection within the window
period. The accuracy of PCR-based assay is extremely
high, even in cases of low viremia in the samples [9].
The occurrence of mutant strains of HBV has been
reported in different parts of the world [20, 27, 30, 38].
PCR assay revealed that some HBsAg-positive samples
lack the presence of viral DNA, which indicates a falsepositive result. The underlying causes of false-positive
results are multifold and include viral mutation,
drugs/medication, vaccine-induced HBsAg reactivity,
and differences in the specificity of the test kits used
[39-41]. PCR-based assays have long been employed to
detect and diagnose bacterial, parasites, and viral
infections. This method has proven to be reliable and
yields higher sensitivity and specificity compared with
other methods, such as microscopy or rapid test kits [4246]. Several studies have evaluated the diagnostic
accuracy and superiority of PCR-based assay in
diagnosing infections and compared the method with
rapid test kit assays [9, 42, 44, 47–49].
The high prevalence of HBsAg and HBV DNA in the
population under study highlights the need for
stakeholders to take appropriate measures to prevent the
further spread of infection. Because accurate detection
of HBV is of great importance, the rapid test kit method
cannot be recommended as the sole assay for HBV
screening; instead, employment and total incorporation
of viral DNA molecular assay in all screenings
involving HBV should be considered. This measure
may help reduce the incidence of HBV false-negative
results reported for blood screening cases and enable
accurate and proper diagnosis.
The recruitment of only female patients to this study
may have been a limitation to this work and may have
introduced bias to the findings in this study.

Conclusion
The present study revealed the high prevalence of
HBsAg in the studied population. It also showed high
levels of false-negative results, which indicates the
presence of HBV mutant strains and the limited
detection and sensitivity of commercial rapid test kits
for detecting genetic variations in HBsAg. PCR
molecular-based assay was confirmed to have robust
sensitivity and detection capability for detecting viral
Makara J. Sci.
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DNA. The results stress the need for total incorporation
of PCR-based HBV diagnostics in all blood screening
cases. Further investigations, perhaps with a larger
population size, are necessary to ascertain the HBV
geno- and mutation type(s) circulating in the population
and obtain a better understanding of the characteristics
of HBV infection.
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